Recombinant Rat ADCYAP1R1 Protein Pre-coupled Magnetic Beads
Cat.No. : | ADCYAP1R1-177R-B |
Product Overview : | The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Rat |
Form : | Solution |
Particle size : | ~2 μm |
Beads Surface : | Hydrophilic |
Capacity : | > 200 pmol rabbit IgG/ mg beads |
Applications : | Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification. |
Stability : | Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. |
Storage : | 2-8℃. Do not to freeze thaw the Beads |
Concentration : | 10mg beads/mL |
Storage Buffer : | PBS buffer |
Gene Name : | Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1 [ Rattus norvegicus ] |
Official Symbol : | ADCYAP1R1 |
Gene ID : | 24167 |
mRNA Refseq : | NM_001270579.1 |
Protein Refseq : | NP_001257508.1 |
UniProt ID : | P32215 |
Products Types
◆ Recombinant Protein | ||
ADCYAP1R1-177R | Recombinant Rat ADCYAP1R1 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADCYAP1R1-521R | Recombinant Rat ADCYAP1R1 Protein | +Inquiry |
ADCYAP1R1-335H | Recombinant Human ADCYAP1R1 Protein, GST-tagged | +Inquiry |
ADCYAP1R1-510H | Recombinant Human ADCYAP1R1 Protein, Fc-tagged | +Inquiry |
ADCYAP1R1-3708C | Recombinant Chicken ADCYAP1R1 | +Inquiry |
◆ Lysates | ||
ADCYAP1R1-1642HCL | Recombinant Human ADCYAP1R1 cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-2175 | ADCYAP1R1 CHO-K1 β-Arrestin GPCR Assay Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (14)
Ask a questionADCYAP1R1 protein therapy is not currently approved by the FDA for the treatment of mental health disorders. It is still in the experimental stages of development and clinical trials.
Side effects of ADCYAP1R1 protein therapy may include injection site reactions, fatigue, and dizziness. However, side effects are generally mild and resolve quickly.
ADCYAP1R1 protein therapy may be particularly effective in treating mental health disorders in individuals who have not responded to or cannot tolerate standard treatments such as psychotherapy or medication. Additionally, it may be effective in individuals with PTSD or depression who have elevated levels of stress hormones. Further research is needed to identify specific patient populations who may benefit from this treatment.
One of the main challenges associated with the development and use of ADCYAP1R1 protein therapy is the need for further research to determine its therapeutic potential and safety. Additionally, there may be issues related to cost and access to this type of treatment.
ADCYAP1R1 protein therapy is administered through intravenous injection, nasal spray, or subcutaneous injection.
Currently, there are no alternative treatments that work similarly to ADCYAP1R1 protein therapy. However, there are other treatments such as medication, therapy, and lifestyle changes that have been shown to be effective in the treatment of mental health disorders.
ADCYAP1R1 protein therapy is not a cure for mental health disorders. It is a potential treatment option that may provide relief from symptoms and improve quality of life for individuals with certain conditions. Regular and ongoing treatment may be necessary for long-term management of mental health disorders.
The time it takes for ADCYAP1R1 protein therapy to start working can vary among individuals, and studies examining its efficacy are ongoing. However, some studies have shown that improvements in symptoms may be seen within the first weeks of treatment.
ADCYAP1R1 protein therapy has shown promising results in the treatment of generalized anxiety disorder. However, more research is needed to determine its effectiveness for other types of anxiety disorders, such as panic disorder or social anxiety disorder.
ADCYAP1R1 protein therapy has shown potential for treating mental health conditions such as anxiety, post-traumatic stress disorder (PTSD), and depression. It has also been studied for its potential use in the treatment of Parkinson's disease and chronic pain.
ADCYAP1R1 protein therapy works by targeting a specific receptor in the brain called the pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1R). This receptor is involved in many important brain processes, including stress response, mood regulation, and memory formation.
ADCYAP1R1 protein therapy is not currently a first-line treatment for anxiety disorders. It is considered a second-line or adjunct treatment option for patients who have not responded to or cannot tolerate standard treatments such as antidepressants or benzodiazepines.
The potential benefits of ADCYAP1R1 protein therapy include the reduction of anxiety symptoms, such as excessive worry, restlessness, and difficulty sleeping.
The side effects of ADCYAP1R1 protein therapy are not well-known because it is still in the experimental stages of development. However, potential side effects could include headache, fatigue, nausea, and allergic reactions.
Ask a Question for All ADCYAP1R1 Products
Required fields are marked with *
My Review for All ADCYAP1R1 Products
Required fields are marked with *
Inquiry Basket